{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T06:05:38Z","timestamp":1778997938673,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Introduction: This retrospective study aimed to compare the efficacy and safety of transarterial chemoembolization plus lenvatinib and programmed death 1 (PD-1) inhibitors versus transarterial chemoembolization plus lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma. Methods: Consecutive patients with unresectable hepatocellular carcinoma who received transarterial chemoembolization plus lenvatinib and PD-1 inhibitors, lenvatinib, or sorafenib were retrospectively identified in our institution between January 2018 and August 2020. The primary endpoint was overall survival. Results: A total of 84 patients were included in this analysis. The median overall survival was significantly improved in the transarterial chemoembolization plus lenvatinib and PD-1 inhibitor group compared with the transarterial chemoembolization plus sorafenib group (26.7 months [95% confidence interval 25.2-31.6] vs 14.4 months [95% confidence interval 9.5-18.9]; hazard ratio 0.39 [95% confidence interval 0.17-0.72]; P\u2009\u2009=\u2009\u2009.007) or the transarterial chemoembolization plus lenvatinib group (26.7 months [95% confidence interval 25.2-31.6] vs 17.9 [95% confidence interval 13.4-22.2] months; hazard ratio 0.45 [95% confidence interval 0.17-0.87]; P\u2009\u2009=\u2009\u2009.031). Transarterial chemoembolization plus lenvatinib and PD-1 inhibitor also significantly prolonged median progression-free survival compared with transarterial chemoembolization plus sorafenib group (8.2 months [95% confidence interval 3.3-13.0] vs 6.0 months [95% confidence interval 4.2-7.8]; hazard ratio 0.47 [95% confidence interval 0.24-0.74]; P\u2009\u2009=\u2009\u2009.005) or the transarterial chemoembolization plus lenvatinib group (8.2 months [95% confidence interval 3.3-13.0] vs 6.6 [95% confidence interval 4.3-7.9] months; hazard ratio 0.58 [95% confidence interval 0.31-0.96]; P\u2009\u2009=\u2009\u2009.047). No significant difference was seen between groups in the incidence of an adverse event or grade 3 or higher adverse event. Conclusion: Transarterial chemoembolization plus lenvatinib, and PD-1 inhibitor was associated with better survival benefits and acceptable toxicities, which may provide an additional therapeutic option for unresectable hepatocellular carcinoma.<\/jats:p>","DOI":"10.1177\/15330338221133640","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T03:07:39Z","timestamp":1666148859000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis"],"prefix":"10.1177","volume":"21","author":[{"given":"Shu","family":"Zhao","sequence":"first","affiliation":[{"name":"The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhang","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yin","sequence":"additional","affiliation":[{"name":"The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3580-3631","authenticated-orcid":false,"given":"Peng","family":"Song","sequence":"additional","affiliation":[{"name":"The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"bibr1-15330338221133640","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"bibr2-15330338221133640","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338"},{"key":"bibr3-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13359"},{"key":"bibr4-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23725"},{"key":"bibr5-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1159\/000480256"},{"key":"bibr6-15330338221133640","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i19.2878"},{"key":"bibr7-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1080\/02841850801958890"},{"key":"bibr8-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"bibr9-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"bibr10-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"bibr11-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01307"},{"key":"bibr12-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00604-5"},{"key":"bibr13-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.383"},{"key":"bibr14-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"bibr15-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808"},{"key":"bibr16-15330338221133640","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050532"},{"key":"bibr17-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913"},{"key":"bibr18-15330338221133640","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"bibr19-15330338221133640","doi-asserted-by":"publisher","DOI":"10.2174\/138945010791591395"},{"key":"bibr20-15330338221133640","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22078"},{"key":"bibr21-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13191"},{"key":"bibr22-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0504-2"},{"key":"bibr23-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"bibr24-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.025"},{"key":"bibr25-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-017-9552-y"},{"key":"bibr26-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31921"},{"key":"bibr27-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.05.007"},{"key":"bibr28-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.012"},{"key":"bibr29-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318934"},{"key":"bibr30-15330338221133640","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33677"},{"key":"bibr31-15330338221133640","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.609322"},{"key":"bibr32-15330338221133640","author":"Chen S","journal-title":"J Cancer Res Clin Oncol"},{"key":"bibr33-15330338221133640","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i22.2994"},{"key":"bibr34-15330338221133640","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.950536"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338221133640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338221133640","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338221133640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:11:39Z","timestamp":1777702299000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338221133640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":34,"alternative-id":["10.1177\/15330338221133640"],"URL":"https:\/\/doi.org\/10.1177\/15330338221133640","relation":{},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"15330338221133640"}}